Is UNVO undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6
Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of UNVO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate UNVO's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate UNVO's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for UNVO?
Key metric: As UNVO is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
The above table shows the Price to Sales ratio for UNVO. This is calculated by dividing UNVO's market cap by their current
revenue.
What is UNVO's PS Ratio?
PS Ratio
0.06x
Sales
₪43.89m
Market Cap
₪2.84m
UNVO key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Price-To-Sales vs Industry: UNVO is good value based on its Price-To-Sales Ratio (0.1x) compared to the Asian Biotechs industry average (9.9x).
Price to Sales Ratio vs Fair Ratio
What is UNVO's PS Ratio
compared to its
Fair PS Ratio?
This is the expected PS Ratio taking into
account the company's forecast earnings growth, profit margins
and other risk factors.
UNVO PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio
0.06x
Fair PS Ratio
n/a
Price-To-Sales vs Fair Ratio: Insufficient data to calculate UNVO's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
7D
1Y
7D
1Y
7D
1Y
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2023/03/14 13:46
End of Day Share Price
2022/12/15 00:00
Earnings
2022/06/30
Annual Earnings
2021/12/31
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Univo Pharmaceuticals Ltd is covered by 0 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.